These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38409713)

  • 21. Psychosis in Alzheimer's Disease.
    Ballard C; Kales HC; Lyketsos C; Aarsland D; Creese B; Mills R; Williams H; Sweet RA
    Curr Neurol Neurosci Rep; 2020 Oct; 20(12):57. PubMed ID: 33048274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavioral or neuropsychiatric symptoms of Alzheimer's disease: from psychopathology to pharmacological management.
    Teixeira AL; Rocha NP; Gatchel J
    Arq Neuropsiquiatr; 2023 Dec; 81(12):1152-1162. PubMed ID: 38157881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.
    Nagata T; Shinagawa S; Nakajima S; Plitman E; Mihashi Y; Hayashi S; Mimura M; Nakayama K
    J Alzheimers Dis; 2016; 50(3):839-45. PubMed ID: 26836181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic treatment patterns in Alzheimer's disease patients with agitation: a cohort study using the UK clinical practice research datalink.
    Tran CT; Bøg M; Collings SL; Johnson M; Qizilbash N; Lind S; Baker RA; Jørgensen KT
    Curr Med Res Opin; 2022 Mar; 38(3):409-416. PubMed ID: 35068266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease.
    Miller LJ
    Consult Pharm; 2007 Sep; 22(9):754-62. PubMed ID: 18198970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments.
    Liu CS; Ruthirakuhan M; Chau SA; Herrmann N; Carvalho AF; Lanctôt KL
    Curr Alzheimer Res; 2016; 13(10):1134-44. PubMed ID: 27137221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropsychiatric Symptoms of Alzheimer's Disease: An Anatomic-Genetic Framework for Treatment Development.
    Nowrangi MA; Outen JD; Kim J; Avramopoulos D; Lyketsos CG; Rosenberg PB
    J Alzheimers Dis; 2023; 95(1):53-68. PubMed ID: 37522204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole.
    Madhusoodanan S; Shah P
    Clin Interv Aging; 2008; 3(3):491-501. PubMed ID: 18982919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus.
    Kales HC; Lyketsos CG; Miller EM; Ballard C
    Int Psychogeriatr; 2019 Jan; 31(1):83-90. PubMed ID: 30068400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological management of behavioral disturbances in patients with Alzheimer's disease.
    Nagata T; Shinagawa S; Nakajima S; Noda Y; Mimura M
    Expert Opin Pharmacother; 2020 Jun; 21(9):1093-1102. PubMed ID: 32281891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease.
    Tartaglia MC; Hu B; Mehta K; Neuhaus J; Yaffe K; Miller BL; Boxer A
    Alzheimer Dis Assoc Disord; 2014; 28(2):182-9. PubMed ID: 23995817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease.
    Panza F; Frisardi V; Seripa D; D'Onofrio G; Santamato A; Masullo C; Logroscino G; Solfrizzi V; Pilotto A
    Ageing Res Rev; 2012 Jan; 11(1):87-103. PubMed ID: 21763789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gray matter volumes and treatment response of psychotic symptoms to risperidone in antipsychotic-naïve Alzheimer's disease patients.
    Lee YM; Park JM; Lee BD; Moon E; Jeong HJ; Chung YI; Kim JH; Kim HJ; Mun CW; Kim TH; Kim YH
    J Clin Psychiatry; 2016 Jan; 77(1):e8-13. PubMed ID: 26845282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of antidepressants and antipsychotics as a novel treatment option for psychosis in Alzheimer's disease.
    Fan P; Zeng L; Ding Y; Kofler J; Silverstein J; Krivinko J; Sweet RA; Wang L
    CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1119-1131. PubMed ID: 37128639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy difference of antipsychotics in Alzheimer's disease and schizophrenia: explained with network efficiency and pathway analysis methods.
    Fan P; Kofler J; Ding Y; Marks M; Sweet RA; Wang L
    Brief Bioinform; 2022 Nov; 23(6):. PubMed ID: 36151774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study.
    Nagata T; Nakajima S; Shinagawa S; Plitman E; Nakayama K; Graff-Guerrero A; Mimura M
    J Alzheimers Dis; 2017; 60(1):263-272. PubMed ID: 28800334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific Neuropsychiatric Symptoms Are Associated with Faster Progression in Alzheimer's Disease: Results of the Prospective Dementia Registry (PRODEM-Austria).
    Defrancesco M; Marksteiner J; Kemmler G; Dal-Bianco P; Ransmayr G; Benke T; Mosbacher J; Höller Y; Schmidt R
    J Alzheimers Dis; 2020; 73(1):125-133. PubMed ID: 31744004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease.
    Heilman KM; Nadeau SE
    Neurotherapeutics; 2022 Jan; 19(1):99-116. PubMed ID: 35013934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychosis-related disturbances. Psychosis, agitation, and disinhibition in Alzheimer's disease: definitions and treatment options.
    Lesser JM; Hughes S
    Geriatrics; 2006 Dec; 61(12):14-20. PubMed ID: 17184138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.